The anticonvulsant agent phenytoin (5,5-diphenylhydantoin) is mainly excreted as 5-(4?-hydroxyphenyl)-5-phenylhydantoin (4?-HPPH) O-glucuronide in humans. Previously, we demonstrated that the glucuronidation of 4?-HPPH is catalyzed by multiple UDP-glucuronosyltransferases (UGTs) of UGT1A1, UGT1A4, UGT1A6, and UGT1A9. Since 4?-HPPH may be bioactivated to a reactive metabolite by peroxidase, the glucuronidation in considered to be a detoxiˆcation pathway. In the present study, we investigated the relationship between the extent of interindividual variability in the urinary excretion levels of 4?-HPPH and its O-glucuronide and genotyping of CYP2C9, CYP2C19, UGT1A1, UGT1A6, and UGT1A9. 4?-HPPH and its glucuronide in urine samples from 15 patients to whom phenytoin was administered were measured by liquid chromatography-tandem mass spectrometry. When the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH was calculated as an index of glucuronidation, a large interindividual variability (11 fold) was observed in the 15 patients. Phenytoin is metabolized to 4?-HPPH by CYP2C9 and CYP2C19 in which there are genetic polymorphisms. Although 5 patients were genotyped as heterozygotes of mutated alleles of CYP2C9 or CYP2C19 genes, no relationship with the interindividual diŠerence in the total excretion levels of 4?-HPPH and its O-glucuronide was observed. The UGT1A1 * 6, UGT1A1 * 28, UGT1A1 * 60 and UGT1A6 * 2 alleles were found in 1, 3, 6, and 8 patients, respectively. Although there was no relationship between the genetic polymorphisms of UGT1As and the interindividual diŠerence in the 4?-HPPH glucuronidation, the large interindividual variability of 4?-HPPH glucuronidation may contribute to interindividual diŠerences in toxic reactions to phenytoin.
Introduction
Phenytoin (5,5-diphenylhydantoin) is a widely used anticonvulsant drug. Hypersensitivity reactions induced by phenytoin occur in 5 to 10z of patients. 1) The relationship between the phenytoin dose and the resulting concentration in the serum varies markedly between individuals for reasons not fully clariˆed. Because of its narrow therapeutic range (10-20 mg W mL) and nonlinearity in the blood concentration, 2) therapeutic drug monitoring is usually recommended. This drug undergoes extensive metabolic conversion in the liver, with º5z of an administered dose being excreted in the urine in the unchanged form.
3) Phenytoin is mainly metabolized to 5-(4?-hydroxyphenyl)-5-phenylhydantoin (4?-HPPH) (Fig. 1) . The formation of 4?-HPPH is catalyzed mainly by cytochrome P450 (CYP) 2C9, and to a minor extent, by CYP2C19 in humans. 4, 5) 4?- HPPH is present in plasma almost entirely as a glucuronic acid conjugate. Some 75z of administered phenytoin appear in urine as 4?-HPPH O-glucuronide.
6)
Since 4?-HPPH alternatively may be bioactivated by peroxidase to a reactive intermediate, which can oxidize lipids, proteins, and DNA, [7] [8] [9] the glucuronidation may prevent competing bioactivation of 4?-HPPH to a toxic reactive intermediate.
The glucuronidation of endogenous compounds and xenobiotics is catalyzed by UDP-glucuronosyltransferases (UGTs) which compose a superfamily. UGTs exist as two families, UGT1 and UGT2. UGT1 isoforms are produced by alternative splicing of the UGT1 gene complex. Recently, we reported that multiple UGT1A isoforms (UGT1A1, UGT1A4, UGT1A6, and UGT1A9) are involved in the glucuronosyltransferase activity of 4?-HPPH in humans. 10) Furthermore, a large interindividual diŠerence in the glucuronosyltransferase activity of 4?-HPPH was shown in liver microsomes from 14 humans. 10) However, there is little information regarding the interindividual variability of the in vivo glucuronosyltransferase activity of 4?-HPPH.
In the present study, to evaluate the interindividual variability of 4?-HPPH glucuronidation, we measured 4?-HPPH and its O-glucuronide in urine from patients to whom phenytoin was administered. In addition, the relationship between the interindividual variability and the genetic polymorphisms of UGT1A isoforms in the patients was investigated.
Materials and Methods
Chemicals and regents: 4?-HPPH and b-glucuronidase from Helix pomatia (Type H-2) were from SigmaAldrich (St. Louis, MO). A Puregene DNA isolation kit was obtained from Gentra Systems (Minneapolis, MN). Taq DNA polymerase was from Greiner Japan (Tokyo, Japan). Restriction enzymes were purchased from Toyobo (Osaka, Japan), Takara (Kyoto, Japan), or New England Biolabs (Beverly, MA). Other chemicals were of the highest grade commercially available.
Patients: This study was approved by the Ethics Committee of Kanazawa University and all the participants gave written informed consent. Fifteen patients (10 males and 5 females) in Kanazawa University Hospital with normal renal and hepatic functions who received phenytoin were studied ( Table 1) . The ages ranged from 18 to 64 years. The daily phenytoin dose varied from 180 to 300 mg. The serum concentration of phenytoin in all patients was expected to be in the steady state, since it has been reported that steady state serum phenytoin levels are achieved 7 to 10 days after phenytoin therapy is begun.
11) The serum concentrations of phenytoin in patients were measured by ‰uorescence polarization immunoassay (TDX, Dinabot, Tokyo, Japan) as part of a regular monitoring schedule. Urine samples for an entire 24 hr period were collected and frozen at -209 C until analyzed.
Sample preparation: To 0.5 mL urine, 0.5 mL of 0.4 M potassium phosphate buŠer (pH 7.4) were added. The mixture was extracted with 4 mL of diethyl ether by shaking for 10 min. The organic fraction was transferred to a clean tube and evaporated under a gentle stream of nitrogen at 409 C. The residue was redissolved in 100 mL of mobile phase and thenˆltrated with a 0.22 mmˆlter (Ultrafree } -MC centrifugalˆlter unit, Millipore, Eschborn, Germany). Aliquots of 5 mL were injected into the LC-MS W MS system. For the determination of glucuronide, urine samples were treated with b-glucuronidase, 12) and measured as 4?-HPPH. To 100 mL urine samples, 800 U W mL of b-glucuronidase were added, and the mixture was incubated at 379 C for 10 hr. After the hydrolysis, the samples were treated as described above.
LC-MS W MS analysis of 4?-HPPH: Liquid chromatography (LC) was performed using an HP 1100 system including a binary pump, an automatic sampler, and a column oven (Agilent Technologies, Waldbronn, Germany), which was equipped with an Inertsil ODS-3 (4.6×250 mm; 5 mm) column (GL Science, Tokyo, Japan). The column temperature was 359 C. The mobile phase was 0.05z formic acid (A) and acetnitrile (B). The conditions for elution was as follows: 30z B (0-18 Turbo gas was maintained at 5009 C. Nitrogen was used as the nebulizing, turbo, and curtain gas at 40, 90, 40 psi, respectively. Parent and W or fragment ions werê ltered in theˆrst quadrupole and dissociated in the collision cell using nitrogen as the collision gas. The collision energy was -32 V. Mass W charge (m W z) ion transition was recorded in the multiple reaction monitoring (MRM) mode: m W z 267 and 118. The retention time of 4?-HPPH was 17.0 min. The limit of detection for 4?-HPPH (signal-to-noise ratio 3:1) was 0.4 pmol. The limit of quantiˆcation in urine was 2 mM, and it was su‹ciently low to quantify 4?-HPPH in urine samples. Linearity was conˆrmed up to 100 mM and the recovery of 4?-HPPH ranged from 81 to 86z. Intra-day and inter-day precision and accuracy were conˆrmed to be º10z.
Genotyping: Genomic DNA was extracted from peripheral lymphocytes using a Puregene DNA isolation kit. Genotyping for CYP2C9*3 (A1075C, Ile359Leu), CYP2C19 * 2 (G681A, splicing defect), and CYP2C19 * 3 (G636A, stop codon) was performed by PCR-restriction fragment length polymorphism (RFLP) with the restriction enzymes of Nsi I, Sma I, and BamH I, respectively. [13] [14] [15] UGT1A1*6 (G211A, Gly71Arg), UGT1A1 * 7 (T1456G, Tyr486Asp), and UGT1A1 * 27 (C686A, Pro229Gln) alleles were genotyped according to a method reported by Ando et al.
16) The genotyping methods for UGT1A1 * 25 (C840A, stop codon), UGT1A1*28 (A(TA)7TAA), UGT1A1*29 (C1099G, Arg367Gly), UGT1A1 * 38 (C991T, stop codon), UGT1A1*60 (T-3263G), UGT1A1*62 (T247C, Phe83Leu), UGT1A6*2 (A541G, Thr181Ala and A552C, Arg184Ser), UGT1A6 * 3 (A552C, Arg184Ser), UGT1A9*4 (T726G, stop codon), and UGT1A9*5 (G766A, Asp256Asn) alleles by PCR-RFLP, PCRsingle strand conformation polymorphism (SSCP) or allele-speciˆc (AS)-PCR were developed in the present study ( Table 2) . Genomic DNA samples (0.1 mg) were added to the PCR mixtures (25 mL) consisting of 1X PCR buŠer [67 mM Tris-HCl buŠer (pH 8.8), 16.6 mM (NH 4 ) 2 SO 4 , 0.45z Triton X-100, 0.02z gelatin], 1.5 mM MgCl2, 0.4 mM primers, 250 mM dNTPs, and 1 U of Taq DNA polymerase. After an initial denaturation at 949 C for 3 min, the ampliˆcation was performed by denaturation at 949 C for 30 sec, annealing for 30 sec, and extension at 729 C for 30 sec for 30 cycles. Theˆnal extension step was performed at 729 C for 5 min. Primer sets, restriction enzymes for PCR-RFLP analysis, annealing temperatures, and fragment lengths are summarized in Table 2 . For PCR-SSCP analyses of the UGT1A1*28 and UGT1A1*60 alleles, the PCR products were denatured for 5 min at 809 C with a 5 fold volume of formamide loading dye (96z formamide, 20 mM EDTA (pH 8.0), 0.1z bromophenol blue, and 0.1z xylene cyanol) and loaded onto a 12.5z polyacrylamide gel with 10z glycerol at 259 C and 49 C, respectively. After electrophoresis, the gels were stained with a silver staining kit (Amersham, Buckinghamshire, UK). To conˆrm the results of the PCR-SSCP analysis, DNA sequencing analysis was performed. The PCR 
GT-3?
The underlined nucleotides indicate mismatched sites.
Statistical analyses:
The relationships between the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH and UGT1A genotype were investigated by Student's t-test.
Results

Excretion of 4?-HPPH and its O-glucuronide in urine at each sampling time:
To evaluate the variability of the excretion levels of phenytoin metabolites during one day, urine samples were collected for 24 hr at various sampling times from 4 patients. Several days later, urine sampling for 24 hr was performed again in the same 4 patients (Fig. 2) . Inter-day diŠerences in the 24-hr accumulated excretion levels of 4?-HPPH and its O-glucuronide in urine: Since there were large diŠerences in the excretion level of 4?-HPPH and its O-glucuronide throughout the day, 24-hr accumulated urine samples were adopted to evaluate the variability of 4?-HPPH glucuronidation. The urine samples collected from a patient during 24 hr were combined. The 24-hr accumulated urine samples were obtained twice from 4 patients at intervals of sever- al days. As shown in Fig. 3 , the accumulated excretion levels of 4?-HPPH and its O-glucuronide showed similar values between the 2 samples in each patient. Furthermore, the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH was also reproducible in each patient. Therefore, in the following study, interindividual diŠerences in the glucuronidation of 4?-HPPH were evaluated with the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH in the 24-hr accumulated urine samples.
Interindividual diŠerences in the accumulated excretion levels of 4?-HPPH and its O-glucuronide in urine: In addition to the above 4 patients, 24-hr accumulated urine samples were collected from 11 patients. The volumes of the 24-hr accumulated urine in 15 patients ranged from 659 mL to 3,464 mL. The accumulated urinary excretion level of 4?-HPPH in 15 patients ranged from 0.7z (patient 5) to 5.7z (patient 7) of the daily dose of phenytoin (Fig. 4A) (Fig. 4B) , showing a large, 11-fold interindividual diŠerence. Patients 5 and 7 exhibited a lower molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH than the other patients.
Genotype of CYP2C9, CYP2C19, UGT1A1, UGT1A6, and UGT1A9: Genomic DNA was not available from patient 7. As shown in Table 3 , patient 6 was genotyped as a heterozygote of CYP2C9 * 3. Patients 1 and 5 were genotyped as heterozygotes of CYP2C19*2. Patients 10 and 14 were genotyped as heterozygotes of CYP2C19 * 3. Concerning the genetic polymorphism of the UGT1A1 gene, patient 1 and 13 were genotyped as a heterozygote of UGT1A1 * 28 and UGT1A1*60. Patient 2 was genotyped as a heterozygote of UGT1A1*28 and a homozygote of UGT1A1*60. Patients 4, 9, and 11 were heterozygotes of UGT1A1*60. Patients 15 was homozygotes of UGT1A1 * 6. Concerning the genetic polymorphism of the UGT1A6 gene, patients 1 and 15 were homozygotes of UGT1A6*2 and patients 2, 3, 9, 11, 12, and 13 were heterozygotes of UGT1A6 * 2. The UGT1A9 * 4 and UGT1A9*5 alleles were not found in the 14 patients. There was no signiˆcant diŠerence in the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH in the heterozygotes of UGT1A1*28 (37.0±3.7, n＝3) and the subjects who does not possessing the UGT1A1 * 28 allele (27.3±18.3, n＝11) ( p＝0.394). There was no signiˆcant diŠerences between the ratios in the heterozygotes of UGT1A1*60 (37.3±16.9, n＝5) and those in the subjects who dose not possessing the UGT1A1*60 allele (24.4±16.3, n＝8) ( p＝0.199). Concerning the UGT1A6*2 allele, no signiˆcant diŠerence was observed in the ratios in the homozygous UGT1A6 * 2 (47.7, n＝2), the heterozygous UGT1A6*2 (33.0±17.6, n＝6), and the homozygous wild-type (20.4±12.1, n＝6) ( p＝0.179).
Discussion
In the present study, urinary excretion levels of 4?-HPPH and its O-glucuronide in patients who were taking phenytoin were determined to evaluate the interindividual diŠerence in the glucuronidation of 4?-HPPH. Phenytoin is metabolized to 4?-HPPH by CYP2C9 and to a minor extent by CYP2C19. 4, 5) There are genetic polymorphisms in CYP2C9 and CYP2C19 genes. Twelve and 19 polymorphic alleles have been reported for the CYP2C9 and CYP2C19 genes, respectively. Concerning the polymorphism of the CYP2C9 gene in Japanese, CYP2C9*3 has been found with the allele frequency of 0.018. 17) For the CYP2C19 gene, the two alleles CYP2C19 * 2 and CYP2C19 * 3 can account for À99z of the defective alleles in oriental populations.
18) Therefore, we also determined these CYP2C9 and CYP2C19 alleles in the patients.
First, the large variation within a day in the urinary excretion levels of 4?-HPPH and its O-glucuronide was demonstrated. Therefore, the 24-hr accumulated urinary excretion levels of phenytoin metabolites were measured to evaluate the inter-day and interindividual diŠerences in the glucuronidation of 4?-HPPH. In general, the ratio of the concentration of a metabolite to the unchanged drug has been employed to investigate the metabolic capacity in population studies. Accordingly, the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH was calculated as an index of the glucuronidation of 4?-HPPH. In 15 patients, a large interindividual diŠerence (11-fold) in the molar ratio of 4?-HPPH O-glucuronide W 4?-HPPH was observed. This result was similar to that of our previous study that showed 28-fold interindividual diŠerences in the 4?-HPPH glucuronide formation in microsomes from 14 human livers.
10)
Previously, we found that the glucuronidation of 4?-HPPH is catalyzed by multiple UGT1As of UGT1A1, UGT1A4, UGT1A6, and UGT1A9.
10) The genetic polymorphisms of the UGT1A1, UGT1A6, and UGT1A9 genes have been reported (http: W W som.‰inders.edu.au W FUSA W ClinPharm W UGT W ). In the Japanese population, 9 alleles of the UGT1A1 gene (UGT1A1*6, UGT1A1 * 7, UGT1A1 * 25, UGT1A1 * 27, UGT1A1 * 28, UGT1A1*29, UGT1A1*38, UGT1A1*60, and UGT1A1*62) and 2 alleles of the UGT1A9 gene (UGT1A9*4 and UGT1A9*5) have been found. 16, [19] [20] [21] [22] [23] [24] [25] In Asian populations, the UGT1A6*2 and UGT1A6*3 alleles have been found. 26) These alleles have been reported to show decreased enzymatic activity of UGT. [20] [21] [22] [23] [27] [28] [29] [30] Therefore, we investigated whether our patients possess these alleles. However, there was no relationship between the genetic polymorphisms of the UGT1A genes investigated in the present study and the interindividual diŠerences in the 4?-HPPH O-glucuronide W 4?-HPPH ratio. In the present study, the sample size might be small to detect the association between the genetic polymorphisms of the UGT1A and 4?-HPPH glucuronidation. Another possibility was that, even if a genetic polymorphism of one UGT1A isoform decreased the enzymatic activity, the other UGT1A isoforms might compensate the 4?-HPPH glucuronosyltransferase activity.
In patient 5, the excretion level of 4?-HPPH Oglucuronide was extremely low. The patient was a heterozygote of CYP2C19 * 2. However, the other patients (patient number 1, 6, 10, and 14) who were also genotyped as heterozygotes of CYP2C9*3, CYP2C19*2 or, CYP2C19 * 3 showed normal excretion levels of 4?-HPPH O-glucuronide. Thus, the eŠects of the heterozygous mutation of CYP2C9 or CYP2C19 genes on the excretion level of 4?-HPPH and its O-glucuronide would be minor. In spite of the decreased metabolism of phenytoin to 4?-HPPH in patient 5, it was conˆrmed the excretion level of phenytoin in the patient was not very high, compared with the other patients (data not shown). Furthermore, the serum concentration of phenytoin was in the therapeutic range, 12.2 mg W mL, with the maintenance dose of 300 mg W day ( Table 1) . Although the possibility was suggested that phenytoin might be preferably metabolized to other metabolites such as 5-(3?-hydroxyphenyl)-5-phenylhydantoin, 5-(3?, 4?-dihydroxyphenyl)-5-phenylhydantoin, or 5-(3?,4?-dihydroxy-1?,5?-cyclohexadien-1-yl)-5-phenylhydantoin, 31) it was conˆrmed that the concentrations of these minor metabolites in the urine sample were low by LC-MS W MS analysis (data not shown). Thus, the cause of the abnormal pharmacokinetics of phenytoin in the patient is unknown. In patient 5, sodium valproate was co-administered with phenytoin ( Table 1) . It is known that valproate aŠects the pharmacokinetics of phenytoin. 32, 33) Valproate has been reported to competitively inhibit CYP2C9 catalyzed tolbutamide hydroxylase activity. 34) Furthermore, it has also been reported that valproate inhibits UGT1A9 catalyzed propofol glucuronidation. 35) Although the possibility of an interaction between valproate and phenytoin should be taken into consideration, it would not be enough to explain the abnormal excretion of 4?-HPPH O-glucuronide.
In conclusion, we found a large interindividual variability in the glucuronidation of 4?-HPPH in patients to whom phenytoin was administered was demonstrated. However, the variability was not related with the polymorphic mutations of the UGT1A1, UGT1A6, and UGT1A9 genes. The variability might be aŠected by other factors except the genetic factor such as diet, environmental factors, state of disease, as that is generally accepted. 36) Since the large interindividual variability of 4?-HPPH glucuronidation may contribute to interindividual diŠerences in toxic reactions to phenytoin or 4?-HPPH, the cause of the variability should be examined further.
